KLIFO invests in new Clinical Trial Supply facility to meet growing demand

Key point summary

• KLIFO makes a substantial investment to meet the projected clinical trial supply (CTS) demand in the market
• The new state-of-the-art CTS and storage facility will be operational in mid-2025
• The expansion plan is positioned to achieve KLIFO’s strategic vision of becoming the leading drug development consultancy in Northern Europeby 2028

KLIFO, a leading North European drug development consultancy, has announced a strategic double-digit million DKK investment to expand its Clinical Trial Supply (CTS) capacity in Denmark.

The investment is to set up a new cutting-edge storage and CTS production facility for the pharmaceutical and biotech industries. The new facility is scheduled for completion by mid-2025, and will triple the company’s CTS footprint, increasing it from 2,000 to 6,000 square metres. The expansion site is ideally situated in the Greater Copenhagen area in Medicon Valley, an internationally recognised life science cluster serving Sweden and Denmark.

Rasmus Nelund, who assumed the position of CEO in May 2023, is spearheading the ambitious project as part of KLIFO28, the company’s innovative strategy. Gilde Healthcare, majority owner of KLIFO, and Nelund’s vision is to firmly establish KLIFO as the leading drug development, clinical operations and clinical trial supply consultancy in Northern Europe by 2028.

“Through this strategic investment, we are fortifying KLIFO’s foothold in the Nordics while laying a robust foundation for the future,” says Nelund. “We are significantly scaling up, tripling the size of our CTS facilities and quadrupling our storage and production capacities to meet the growth we see in the clinical trial supply market in the coming years.”

According to independent market reports, the global CTS solutions market has experienced strong demand and is projected to grow annually at approximately 10% in the coming years. KLIFO is a leading provider of CTS solutions, known for its extensive knowledge and experience in CTS and Quality Assurance (QA). Their expertise has been enhanced through collaborations with competent authorities, placing them at the forefront of the industry.

By mid-year 2025, the new facilities will be completely functional and certified under Good Manufacturing Practices (GMP). Emphasising a commitment to environmental sustainability, the site and its cold rooms and freezers have been meticulously designed to reduce environmental impact. Additionally, these efforts align with certified Environmental, Social, and Governance (ESG) ratings. The fitting out of the new facilities is being carried out separately, ensuring that the current operational capacity will remain unaffected.

“This milestone underscores our deliberate commitment to expanding our flexible and tailor-made CTS solutions. When operational next year, our enhanced facilities will enable us to deliver unparalleled solutions to pharmaceutical and biotech enterprises across the Nordic and European markets,” concludes Christina Vinum, Vice President Clinical Trial Supply Solutions at KLIFO.

For further information, please contact:

Rasmus Nelund
CEO
KLIFO
Phone: +45 44 77 87 93
Email: Rasmus.Nelund@klifo.com

About KLIFO A/S 

KLIFO is an integrated North-European drug development consultancy with significant experience in partnering with pharmaceutical and biotech companies. KLIFO supports clients with strategic advice and operational support and offers end-to-end solutions across all drug development areas, including strategic project management, regulatory affairs, clinical development, clinical trial supply, quality assurance (QA), Chemistry Manufacturing and Controls (CMC) development, non-clinical development and pharmacovigilance in relation to the development of pharmaceutical products. KLIFO has offices in Denmark, Sweden, Germany, and the Netherlands, engaging approximately 200 highly skilled employees and consultants. The private equity fund, Gilde Healthcare, acquired the majority stake in KLIFO in 2021.